The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -26,609,695 | -5,534,069 | -4,996,656 | -19,764,713 |
| Stock-based compensation expense | 3,526,710 | 3,956,050 | 2,298,132 | 6,022,287 |
| Amortization of in-process research and development | 1,720,312 | 573,438 | - | - |
| Deferred income tax expense | -231,210 | 264,240 | 264,240 | 792,720 |
| Accounts receivable, net of allowances | -2,970,056 | 4,049,111 | - | - |
| Inventory | 20,248 | 352,649 | 3,709,006 | 8,940,201 |
| Prepaid expenses | -110,553 | 3,431,660 | - | -1,600,000 |
| Accounts payable | -1,563,661 | -2,787,784 | 4,567,265 | 4,955,797 |
| Accrued expenses | 19,538,657 | 425,792 | -4,365,430 | 8,458,554 |
| Due to related party | -3,273,092 | 1,980,807 | 2,049,409 | 6,875,556 |
| Net cash (used in) provided by operating activities | -3,831,618 | -7,354,946 | -5,492,046 | 0 |
| License payments | 600,000 | 4,400,000 | 5,750,000 | - |
| Net cash used in investing activities | -600,000 | -4,400,000 | -5,750,000 | - |
| Deferred financing costs | 169,252 | - | - | - |
| Net proceeds from issuance of common stock | -61,947 | 15,125,489 | 15,166,842 | - |
| Net cash provided by financing activities | -231,199 | 15,125,489 | 15,166,842 | - |
| Net change in cash and cash equivalents | -4,662,817 | 3,370,543 | 3,924,796 | 0 |
| Cash and cash equivalents beginning of period | 7,295,451 | 3,924,908 | 112 | - |
| Cash and cash equivalents end of period | 2,632,634 | 7,295,451 | 3,924,908 | - |
CITIUS ONCOLOGY, INC. (CTOR)
CITIUS ONCOLOGY, INC. (CTOR)